Lightnews — Scholar-powered news

Biocat @biocat.cat · 13h

Joan Comella (@sjdhospitalbarcelona.org), moderated by Montse Daban, explores how to safeguard the future of orphan drugs amid evolving regulations—balancing innovation, access, and equity in the treatment of rare diseases

1 1

Biocat @biocat.cat · 13h

🧬Flomics Biotech is pitching its multiomics liquid biopsy platform for early disease detection, with a strong focus on cancer and respiratory illnesses

Biocat @biocat.cat · 13h

Stefanos Theoharis (Onechain Immunotherapeutics), Sandra Garcia (AQuAS), and Nuria Romero (Asphalion), moderated by Robert Fabregat, tackle the challenges of adopting and reimbursing advanced therapies

1

Biocat @biocat.cat · 13h

⚙️ Cristina Batlle (Delegación del Gobierno en Barcelona), David Blánquez (mjnneuro), and Arantxa Sanz (Catalonia.Health) discuss the impact of recent EU regulatory changes on medical technologies and how member states are balancing patient safety with innovation

Biocat @biocat.cat · 14h

💼 Malgorzata Rogalska (Ysios Capital) and Julien Tirefort (Almirall) break down the art and science of due diligence across VC, CVC, and pharma strategies—and how these approaches shape the future of biotech investment and partnerships

Biocat @biocat.cat · 14h

Marc Soriano (Almirall), Maria Terrades (PCB), Avencia Sanchez-Mejias (Integra Therapeutics), Ramón Gras (Aretian), and Jorge Gil (Centrient) explore how R&D Innovation Hubs can drive cross-sector collaboration and unlock the full potential of biotech ecosystems

1 1

Biocat @biocat.cat · 16h

Clara Campàs (Asabys) and Carlota Gómez (HIPRA) discuss how Europe can build strategic autonomy in biotech through local manufacturing, resilient innovation ecosystems, and smarter public-private collaboration

Biocat @biocat.cat · 17h

🧬Telara Pharma is pitching its next-generation therapies for retinal diseases, aiming to preserve and restore vision through targeted, long-lasting treatments.

A must-see pitch!

1

Biocat @biocat.cat · 18h

Natalia Figuera (Genesis Biomed), Lluis Pareras (Invivo Partners), César Velasco (@Astra-Zeneca.bsky.social), Claire Murphy (TECNOMED) & Ignasi Costas (RCD) explore how AI is reshaping healthcare innovation and what it takes to overcome legal, regulatory & investment barriers for real-world impact

1

Biocat @biocat.cat · 19h

Emilio Erazo (Asabys), Xavier Salvatella (Nuage Tx), Anabel Sanz (@crg.eu) and Julia Domingo (@Alloxbio.bsky.social) discuss how to turn pioneering research into high-impact spin-offs

Biocat @biocat.cat · 20h

Day 2 at #BIOSPAIN25 is rolling — and there’s much more ahead!
Partnering, pitches, and big ideas all day.

Stay tuned for highlights 👀

Biocat @biocat.cat · 1d

📢 Our Director, @MontseDaban, is leading the debate on 5P Health and data governance.

Excellent insights from Marco di Donato (@euregha.bsky.social) and Mònica Mateu (BSC) on the future of health data exchange!💡

Biocat @biocat.cat · 1d

🦠 #DevsHealth_cat is pitching their mission to find ultra-fast solutions to infectious diseases.

Using their AI-powered drug discovery platform to combat gram-negative bacteria and emerging viruses!

Biocat @biocat.cat · 1d

José Terencio (Grifols) shares insights on strategic alignment, investment, and pipeline impact through Grifols’ recombinant polyclonal antibody platform

Biocat @biocat.cat · 1d

🎤 Our CEO, Robert Fabregat (#Biocat), joins Ion Arocena (AseBio) to discuss the impact and future of #BIOSPAIN.

1

Biocat @biocat.cat · 1d

Laia Arnal (VHIR) and Rodrigo Dienstmann (VHIO) take part in a solutions-focused discussion on overcoming real-world barriers to #AI in healthcare, and turning innovation into real patient impact.

1

Biocat @biocat.cat · 1d

Inside the Mind of Biotech VCs: With Sara Secall, Clara Campàs & Luis Pareras

Biocat @biocat.cat · 1d

🧠 CONNECTA Therapeutics is pitching their commitment to developing innovative treatments for patients suffering from CNS disorders. Driving R&D to meaningfully improve lives.

Biocat @biocat.cat · 1d

Rafael Navajo (VHIR) joins a roundtable discussion on strengthening preclinical and translational research in Spain through public-private collaboration and innovative strategies.

1

Biocat @biocat.cat · 1d

Laura Rodriguez Gallego (Invivo Partners), Nela Klein (Gyala Therapeutics) and Stefanos Theoharis (Onechain Immunotherapeutics) discuss how to overcome technical, regulatory, and industrial barriers in advanced therapy development through collaboration and innovation.

4

Biocat @biocat.cat · 1d

🎙️ Kicking off with inspiring insights.

The future of biotech starts now!

3

Biocat @biocat.cat · 1d

Thrilled to co-host #BIOSPAIN25 alongside AseBio, Generalitat de Catalunya, and @ajuntamentbcn.bsky.social.

Showcasing Catalan innovation in biotech! ✨

1

Biocat @biocat.cat · 1d

🚀 Good morning from BIOSPAIN 2025!

📍 Fira de Barcelona – Montjuïc
Barcelona is now the European hub for #Biotech innovation. Ready to connect!

2

Biocat @biocat.cat · 2d

Merce de Frias (Ona Therapeutics), and Thomas Harth (Ysios Capital). Plus, explore the exhibition and networking opportunities that will make Barcelona the global capital of biotech this week.

🔗 Full program & more info:

BIOSPAIN 2025

BIOSPAIN is one of the most prominent biotechnology events in Europe and one of the largest in the world, both in terms of one-to-one meetings and the participation of companies from around the globe. More than a third of the attendees come from outside the country. This year, it arrives in Barcelona, one of the leading biotechnology clusters in Southern Europe and one of the most vibrant and innovative cities in the world.

www.biocat.cat

Biocat @biocat.cat · 2d

📌 Don’t miss sessions like “Catalyzing 5P Health: Where Do We Stand Regarding Data?”, moderated by Montse Daban (Biocat), and the roundtable “Science Meets Capital: De-risking Early Biotech to Unlock Investment,” promoted by Biocat with Robert Fabregat (Biocat),

1